Introduction This is the fourth article in the ADC series. If previous articles discussed: The integrated system of antibody–drug conjugates (Series I) The evolution of ADC generations (Series II) Linker and conjugation as the engineering core (Series III) This article moves upstream to a more fundamental question: ADC target selection — which antigens are biologically suitable for ADC development? This article is written for readers without prior ADC experience who want to u